Swiss chemical and pharmaceutical company Lonza is investing in its Guangzhou site to expand production capacity for pharmaceuticals. “The fill and finish production line will significantly expand the site’s capabilities, supporting global and domestic customers with supply for clinical trials and commercial batches in China.” the Basel-based company reported. The expansions are expected to be completed by 2022, creating more than 150 new jobs. Lonza manufactures ingredients for Moderna’s COVID-19 vaccine.
Continue reading now
Get 30 days of free access to the Decision Brief to read these and more quality news every day.
Are you already a guest at the China.Table? Log in now